Paulson & CO. Inc. Invests $13.86 Million in Dova Pharmaceuticals, Inc. (DOVA)

Paulson & CO. Inc. bought a new stake in shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 621,632 shares of the company’s stock, valued at approximately $13,856,000. Paulson & CO. Inc. owned 2.42% of Dova Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Laurion Capital Management LP purchased a new stake in shares of Dova Pharmaceuticals during the second quarter valued at $223,000. JPMorgan Chase & Co. purchased a new stake in shares of Dova Pharmaceuticals during the second quarter valued at $382,000. Vanguard Group Inc. purchased a new stake in shares of Dova Pharmaceuticals during the second quarter valued at $390,000. Goldman Sachs Group Inc. purchased a new stake in shares of Dova Pharmaceuticals during the second quarter valued at $493,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Dova Pharmaceuticals during the second quarter valued at $668,000. 23.52% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Paulson & CO. Inc. Invests $13.86 Million in Dova Pharmaceuticals, Inc. (DOVA)” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/10/17/paulson-co-inc-invests-13-86-million-in-dova-pharmaceuticals-inc-dova.html.

In other news, Director Paul B. Manning bought 25,870 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average cost of $22.30 per share, with a total value of $576,901.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven M. Goldman bought 20,169 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was purchased at an average cost of $22.23 per share, with a total value of $448,356.87. Following the completion of the transaction, the director now owns 81,158 shares in the company, valued at $1,804,142.34. The disclosure for this purchase can be found here.

Shares of Dova Pharmaceuticals, Inc. (NASDAQ DOVA) traded down 1.62% during mid-day trading on Tuesday, hitting $28.00. 29,987 shares of the stock were exchanged. The stock’s market cap is $718.26 million. Dova Pharmaceuticals, Inc. has a 12 month low of $16.98 and a 12 month high of $29.99. The company has a 50-day moving average price of $25.93 and a 200-day moving average price of $24.10.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.08). Equities analysts expect that Dova Pharmaceuticals, Inc. will post ($1.40) earnings per share for the current year.

A number of analysts have recently issued reports on DOVA shares. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Wednesday, October 11th. Jefferies Group LLC started coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They set a “buy” rating and a $30.00 target price for the company. Leerink Swann started coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They set a “market perform” rating and a $24.00 target price for the company. Finally, J P Morgan Chase & Co started coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They set an “overweight” rating and a $35.00 target price for the company.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply